ES8106407A1 - Procedimiento para el tratamiento de superficies hidrofobas - Google Patents

Procedimiento para el tratamiento de superficies hidrofobas

Info

Publication number
ES8106407A1
ES8106407A1 ES494356A ES494356A ES8106407A1 ES 8106407 A1 ES8106407 A1 ES 8106407A1 ES 494356 A ES494356 A ES 494356A ES 494356 A ES494356 A ES 494356A ES 8106407 A1 ES8106407 A1 ES 8106407A1
Authority
ES
Spain
Prior art keywords
proteins
denaturization
utilization
manufacture
aqueous solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES494356A
Other languages
English (en)
Spanish (es)
Other versions
ES494356A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2917535A external-priority patent/DE2917535C2/de
Priority claimed from DE19792952119 external-priority patent/DE2952119A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES494356A0 publication Critical patent/ES494356A0/es
Publication of ES8106407A1 publication Critical patent/ES8106407A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES494356A 1979-04-30 1980-08-19 Procedimiento para el tratamiento de superficies hidrofobas Expired ES8106407A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2917535A DE2917535C2 (de) 1979-04-30 1979-04-30 Gegen Denaturierung beständige Insulinlösungen
DE19792952119 DE2952119A1 (de) 1979-12-22 1979-12-22 Gegen denaturierung bestaendige, waessrige protein-loesungen

Publications (2)

Publication Number Publication Date
ES494356A0 ES494356A0 (es) 1981-07-16
ES8106407A1 true ES8106407A1 (es) 1981-07-16

Family

ID=25778936

Family Applications (1)

Application Number Title Priority Date Filing Date
ES494356A Expired ES8106407A1 (es) 1979-04-30 1980-08-19 Procedimiento para el tratamiento de superficies hidrofobas

Country Status (11)

Country Link
US (1) US4885164A (cg-RX-API-DMAC7.html)
EP (1) EP0018609B1 (cg-RX-API-DMAC7.html)
AU (1) AU535040B2 (cg-RX-API-DMAC7.html)
CA (1) CA1146069A (cg-RX-API-DMAC7.html)
DE (1) DE3064888D1 (cg-RX-API-DMAC7.html)
DK (1) DK160459C (cg-RX-API-DMAC7.html)
EG (1) EG15017A (cg-RX-API-DMAC7.html)
ES (1) ES8106407A1 (cg-RX-API-DMAC7.html)
FI (1) FI70671C (cg-RX-API-DMAC7.html)
GR (1) GR67209B (cg-RX-API-DMAC7.html)
IL (1) IL59933A (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
ATE88352T1 (de) * 1988-02-26 1993-05-15 Genentech Inc Humanes relaxinpraeparat.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
DE19722950A1 (de) * 1997-05-31 1998-12-03 Huels Chemische Werke Ag Renaturierung von Eiweißstoffen
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE59804785D1 (de) 1997-11-22 2002-08-22 Roche Diagnostics Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
CN102625813A (zh) 2008-06-20 2012-08-01 诺华公司 具有降低的聚集的免疫球蛋白
PL3228320T3 (pl) 2008-10-17 2020-06-01 Sanofi-Aventis Deutschland Gmbh Kombinacja insuliny i agonisty GLP-1
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
SI2498801T1 (en) 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
CA3011480C (en) 2009-11-13 2021-11-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
JP2013528570A (ja) 2010-03-31 2013-07-11 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
WO2011121559A2 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
MX379196B (es) 2014-05-07 2025-03-10 Boehringer Ingelheim Int Nebulizador.
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
IL270975B2 (en) 2017-06-01 2024-02-01 Lilly Co Eli Fast-acting insulin preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212695A1 (de) * 1972-03-16 1973-09-20 Hoechst Ag Verfahren zur reinigung von insulin und insulinderivaten
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB1563311A (en) * 1975-09-26 1980-03-26 Yamanouchi Pharma Co Ltd Pharmaceutical composition of insulin for rectal use
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations

Also Published As

Publication number Publication date
DK185180A (da) 1980-10-31
EP0018609A1 (de) 1980-11-12
EP0018609B1 (de) 1983-09-21
CA1146069A (en) 1983-05-10
DK160459C (da) 1991-08-26
GR67209B (cg-RX-API-DMAC7.html) 1981-06-24
FI801361A7 (fi) 1980-10-31
ES494356A0 (es) 1981-07-16
AU535040B2 (en) 1984-03-01
IL59933A (en) 1984-06-29
IL59933A0 (en) 1980-06-30
AU5787780A (en) 1980-11-06
EG15017A (en) 1985-12-31
DE3064888D1 (en) 1983-10-27
DK160459B (da) 1991-03-18
US4885164A (en) 1989-12-05
FI70671C (fi) 1986-10-06
FI70671B (fi) 1986-06-26

Similar Documents

Publication Publication Date Title
ES8106407A1 (es) Procedimiento para el tratamiento de superficies hidrofobas
AU564405B2 (en) Production of stabilized whey protein product
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
HUT44793A (en) Process for production of 19-nor or 19-nor-d-homo stereoids substituated in position 11-beta by alkinylphenil group and medical preparatives containing them as active substance
ATE2113T1 (de) Verfahren zur herstellung von festen arzneimitteln mit troepfchenfoermig aufgebrachten wirkstoffen.
JPS57194787A (en) Culture medium for animal cell
DE3572179D1 (en) Blood coagulation inhibiting proteins, process for preparing them and their use
DE3382387D1 (de) Loesungen von aminosaeuren zur parenteralen naehrung sowie dosierverfahren und verwendung.
EP0155387A3 (en) Fibronolytically active hybrid protein, process for its preparation and pharmaceutical composition
ES2065911T3 (es) Produccion de proteinas en formas activas.
EP0322687A3 (en) Method for the manufacture of a product having at least one substance embedded in a carrier
ES478047A1 (es) Procedimiento para la obtencion de acidos 4-piridon-3-car- boxilicos.
GB1441751A (en) Purification of albumin by thermocoagulation
ATE96167T1 (de) Verfahren zur kristallisation von enzymen.
EP0216742A3 (en) Growth factors
PT87658A (pt) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet loesung enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DK579185D0 (da) Pyrrolobenzimidazoler, fremgangsmaade til fremstilling heraf samt laegemidler med indhold heraf
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
ES8503643A1 (es) Un procedimiento para la preparacion de compuestos de bis (carboxamida)
DE3463509D1 (en) Process for the dissolution of peptides and proteins, solutions thereby obtained and their use
EP0065286A3 (en) Process for the purification or concentration of biologically active proteins, and appropriate means therefor.
ATE3974T1 (de) Verfahren zur herstellung von 4,4'-dinitrostilben-2,2'-disulfonsaeure und deren salzen und deren verwendung.
SE7706425L (sv) Forfarande for framstellning av polyribonukleotider med aktivitet vid alstrandet av leukocyter och blodplettar
IE44288L (en) Preparation of amino acid mixture.
EP0372522A3 (en) Dieting agents comprising alpha-amylase inhibiting substances from wheat